{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T02:19:38Z","timestamp":1777861178322,"version":"3.51.4"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca PLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.lungcan.2026.109343","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T16:52:33Z","timestamp":1771865553000},"page":"109343","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Osimertinib after definitive chemoradiotherapy in patients with unresectable stage III EGFR-mutated NSCLC: LAURA China cohort"],"prefix":"10.1016","volume":"215","author":[{"given":"Xiaorong","family":"Dong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Jian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3390-9697","authenticated-orcid":false,"given":"Meijuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuanghu","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7537-3619","authenticated-orcid":false,"given":"Zhengfei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nan","family":"Bi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingyi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongqing","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena Armenteros","family":"Monterroso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangning","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8833-7262","authenticated-orcid":false,"given":"Shun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2026.109343_b0005","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1002\/cac2.12359","article-title":"Non-small cell lung cancer in China","volume":"42","author":"Chen","year":"2022","journal-title":"Cancer Commun. (lond)."},{"key":"10.1016\/j.lungcan.2026.109343_b0010","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1097\/CM9.0000000000002529","article-title":"Global burden and trends of lung cancer incidence and mortality","volume":"136","author":"Li","year":"2023","journal-title":"Chin. Med. J. (Engl)"},{"key":"10.1016\/j.lungcan.2026.109343_b0015","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-009419","article-title":"Incidence and survival of non-small cell lung cancer in Shanghai: a population-based cohort study","volume":"5","author":"Fan","year":"2015","journal-title":"BMJ Open"},{"key":"10.1016\/j.lungcan.2026.109343_b0020","unstructured":"N.C. Institute, The Surveillance, Epidemiology, and End Results (SEER), 2015. https:\/\/seer.cancer.gov\/. (accessed 14 October 2025)."},{"key":"10.1016\/j.lungcan.2026.109343_b0025","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1200\/JCO.21.02528","article-title":"Management of stage III non-small-cell lung cancer: ASCO guideline","volume":"40","author":"Daly","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109343_b0030","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/j.annonc.2021.08.1994","article-title":"Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice guidelines focusing on diagnosis, staging, systemic and local therapy","volume":"32","author":"Remon","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2026.109343_b0035","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.jtho.2023.02.009","article-title":"Brief report: durvalumab after chemoradiotherapy in unresectable stage III EGFR-mutant NSCLC: a post hoc subgroup analysis from PACIFIC","volume":"18","author":"Naidoo","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2026.109343_b0040","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.annonc.2022.02.003","article-title":"ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer","volume":"33","author":"Passaro","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2026.109343_b0045","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.semcancer.2019.09.015","article-title":"Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer","volume":"61","author":"Harrison","year":"2020","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.lungcan.2026.109343_b0050","first-page":"20","article-title":"Critical review of EGFR-mutated NSCLC what we do and do not know critical review of EGFR-mutated NSCLC what we do and do not know, Healthbook TIMES. Oncology","volume":"3","author":"Meisel","year":"2020","journal-title":"Hematology"},{"key":"10.1016\/j.lungcan.2026.109343_b0055","doi-asserted-by":"crossref","first-page":"78985","DOI":"10.18632\/oncotarget.12587","article-title":"The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"issue":"Suppl 1","key":"10.1016\/j.lungcan.2026.109343_b0060","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1038\/onc.2009.198","article-title":"Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors","volume":"28","author":"Gazdar","year":"2009","journal-title":"Oncogene"},{"key":"10.1016\/j.lungcan.2026.109343_b0065","article-title":"Real-world response and outcomes in patients with NSCLC with EGFR exon 20 insertion mutations","volume":"4","author":"Ou","year":"2023","journal-title":"JTO Clin. Res. Rep."},{"key":"10.1016\/j.lungcan.2026.109343_b0070","doi-asserted-by":"crossref","first-page":"56998","DOI":"10.18632\/oncotarget.10933","article-title":"A retrospective analysis in patients with EGFR-mutant lung adenocarcinoma: is EGFR mutation associated with a higher incidence of brain metastasis?","volume":"7","author":"Han","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.lungcan.2026.109343_b0075","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/JTO.0000000000000069","article-title":"EGFR mutation and brain metastasis in pulmonary adenocarcinomas","volume":"9","author":"Shin","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2026.109343_b0080","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s11060-017-2590-x","article-title":"High probability and frequency of EGFR mutations in non-small cell lung cancer with brain metastases","volume":"135","author":"Ge","year":"2017","journal-title":"J. Neurooncol"},{"key":"10.1016\/j.lungcan.2026.109343_b0085","first-page":"9","article-title":"Osimertinib for EGFR-mutant non-small-cell lung cancer central nervous system metastases: current evidence and future perspectives on therapeutic strategies, Target","volume":"18","author":"Popat","year":"2023","journal-title":"Oncol"},{"key":"10.1016\/j.lungcan.2026.109343_b0090","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","article-title":"AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer","volume":"4","author":"Cross","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.lungcan.2026.109343_b0095","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or platinum\u2013pemetrexed in EGFR T790M\u2013positive lung cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.109343_b0100","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non\u2013small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.109343_b0105","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","article-title":"Osimertinib in resected EGFR-mutated non-small-cell lung cancer","volume":"383","author":"Wu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.109343_b0110","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMoa2402614","article-title":"Osimertinib after chemoradiotherapy in stage III EGFR-mutated NSCLC","volume":"391","author":"Lu","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.109343_b0115","doi-asserted-by":"crossref","unstructured":"S.S. Ramalingam, M. Ozguroglu, M.J. Ahn, et al., LBA4: Osimertinib (osi) after definitive chemoradiotherapy (CRT) in patients (pts) with unresectable (UR) stage III EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC): Updated overall survival (OS) analysis from the LAURA study, J Thorac Oncol. 20 (2025) S123\u2013S124. Presented ELCC 2025. LBA2024 Proffered Paper, doi: 10.1016\/S1556-0864(25)00379-X.","DOI":"10.1016\/S1556-0864(25)00379-X"},{"key":"10.1016\/j.lungcan.2026.109343_b0120","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1200\/JCO-24-01324","article-title":"Management of stage III non-small cell lung cancer: ASCO rapid recommendation update","volume":"42","author":"Daly","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109343_b0125","doi-asserted-by":"crossref","unstructured":"A. Zer, M.J. Ahn, F. Barlesi, et al., Early and locally advanced non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up, Ann Oncol. (2025) Article in Press, doi: 10.1016\/j.annonc.2025.08.003.","DOI":"10.1016\/j.annonc.2025.08.003"},{"key":"10.1016\/j.lungcan.2026.109343_b0130","unstructured":"Food and Drug Administration (FDA), FDA approves osimertinib for locally advanced, unresectable (stage III) non-small cell lung cancer following chemoradiation therapy, 2024. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-osimertinib-locally-advanced-unresectable-stage-iii-non-small-cell-lung-cancer. (accessed 17 April 2025)."},{"key":"10.1016\/j.lungcan.2026.109343_b0135","unstructured":"European Medicines Agency, Tagrisso: EPAR - Procedural steps taken scientific information after authorisation, 2024. https:\/\/www.ema.europa.eu\/en\/documents\/procedural-steps-after\/tagrisso-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf. (accessed 14 October 2025)."},{"key":"10.1016\/j.lungcan.2026.109343_b0140","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.109343_b0145","unstructured":"International Association for the Study of Lung Cancer (IASLC), Staging Manual in Thoracic Oncology, 2nd Edition. Editorial Rx Press. Ram\u00f3n Rami-Porta., 2016. https:\/\/s3.us-east-1.amazonaws.com\/fonteva-customer-media\/00D3i000000D3mbEAC\/qpDjqzbp_8th_staging_manual_2016_hi_res_pdf. (accessed 14 October 2025)."},{"key":"10.1016\/j.lungcan.2026.109343_b0150","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.radonc.2022.10.002","article-title":"Treatment-related pulmonary adverse events induced by chemoradiation and Durvalumab affect survival in locally advanced non-small cell lung cancer","volume":"176","author":"Xu","year":"2022","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.lungcan.2026.109343_b0155","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.ijrobp.2020.11.026","article-title":"Erlotinib versus etoposide\/cisplatin with radiation therapy in unresectable stage III epidermal growth factor receptor mutation-positive non-small cell lung cancer: a multicenter, randomized, open-label, phase 2 trial","volume":"109","author":"Xing","year":"2021","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.lungcan.2026.109343_b0160","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/j.jtho.2024.09.021","article-title":"PL04.13 Aumolertinib maintenance after chemoradiotherapy in stage III non-small-cell lung cancer: interim results of the phase III study (POLESTAR)","volume":"19","author":"Yu","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2026.109343_b0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.107414","article-title":"Targeted treatment for unresectable EGFR mutation-positive stage III non-small cell lung cancer: emerging evidence and future perspectives","volume":"187","author":"Kato","year":"2024","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2026.109343_b0170","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1093\/jrr\/rrs081","article-title":"A modified phase I trial of radiation dose escalation in 3D conformal radiation therapy with concurrent vinorelbine and carboplatin chemotherapy for non-small-cell lung cancer","volume":"54","author":"Lin","year":"2012","journal-title":"J. Radiat. Res."},{"key":"10.1016\/j.lungcan.2026.109343_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102246","article-title":"Comparison of post-chemoradiotherapy pneumonitis between asian and non-asian patients with locally advanced non-small cell lung cancer: a systematic review and meta-analysis","volume":"64","author":"Liu","year":"2023","journal-title":"eClinicalMedicine"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226000875?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226000875?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T03:08:19Z","timestamp":1777518499000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500226000875"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":35,"alternative-id":["S0169500226000875"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109343","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Osimertinib after definitive chemoradiotherapy in patients with unresectable stage III EGFR-mutated NSCLC: LAURA China cohort","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109343","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"109343"}}